1. Does your trust have a familial cancer service or services (for example, as part of a breast care team, family history clinic, or breast clinic) that manage people who could be at an increased risk of breast cancer because of a history of the disease or related cancers in their family? (Yes/No)
a) If no, please answer question 2 - N/A
b) If yes, please answer questions 3-5.
2. If your trust does not have a familial cancer service, where do you refer patients who need to have their familial breast cancer risk assessed?
N/A
3. If your trust does have a familial cancer service, could you please provide us with:
a) The number of referrals your unit has received for assessment of possible familial breast cancer risk for each of the following periods:
Time period
|
Number of referrals
|
1st April 2021-31st March 2022
|
87 (Sept 2021 post covid) – 31 March 2022)
|
1st April 2022-31st March 2023
|
197
|
1st April 2023-31st March 2024
|
290
|
b) How many patients were identified as moderate risk* of breast cancer for each of the following periods:
Time period
|
Number of moderate risk patients
|
1st April 2021-31st March 2022
|
Please see narrative below.
|
1st April 2022-31st March 2023
|
Please see narrative below.
|
1st April 2023-31st March 2024
|
Please see narrative below.
|
c) How many patients were identified as high risk** of breast cancer for each of the following periods:
Time period
|
Number of high-risk patients
|
1st April 2021-31st March 2022
|
Please see narrative below.
|
1st April 2022-31st March 2023
|
Please see narrative below.
|
1st April 2023-31st March 2024
|
Please see narrative below.
|
* As defined by NICE in CG164 - Lifetime risk from age 20 of greater than 17% but less than 30%, or risk between ages 40 and 50 of between 3 to 8%
** As defined by NICE in CG164 - Lifetime risk from age 20 of greater than 30%, or risk between ages 40 and 50 of greater than 8%, or a 10% or greater chance of a gene mutation being harboured in the family
Unfortunately, the information requested is unable to be provided. The Trust does not have this information readily available and to obtain all of the required information would require a manual search which would take in excess of 18 hours as specified under Section 12 of the Freedom of Information Act.
What we can tell you, is that we currently have the following patients in our service:
Identified as moderate risk of breast cancer and undergoing annual mammograms = 514
Identified as moderate risk of breast cancer not yet reached the age to begin annual mammograms =208
Identified as high risk of breast cancer and undergoing annual mammograms = 277
Identified as high risk of breast cancer not yet reached the age to begin annual mammograms = 41
4. Which services do you offer to patients who are assessed as being at increased risk?
|
Moderate risk
|
High risk
|
|
|
|
|
|
|
Information about modifiable risk factors and behavioural changes to reduce risk
|
X
|
X
|
|
|
|
|
|
|
Chemoprevention
|
X
|
X
|
|
|
|
|
|
|
Risk reducing surgery
|
|
Offer referral to commissioned service
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Screening surveillance
|
Moderate risk
|
<30% chance of BRCA/TP53 carrier
|
>30% chance of BRCA carrier
|
Known BRCA mutation
|
>30% chance of TP53 carrier
|
Known TP53 mutation
|
|
|
Annual MRI
|
|
|
|
|
|
|
|
|
20-29
|
|
|
|
Managed by RGC and VHR screening programme
|
|
|
30-39
|
|
|
X
|
|
|
40-49
|
|
|
X
|
|
|
50-59
|
|
|
If dense
|
|
|
60-69
|
|
|
If dense
|
|
|
70+
|
|
|
|
|
|
Annual Mammography
|
|
|
|
|
|
|
|
|
20-29
|
|
|
|
Managed by RGC and VHR screening programme
|
|
|
30-39
|
X
|
X
|
|
|
|
40-49
|
X
|
X
|
X
|
|
|
50-59
|
|
X
|
X
|
|
|
60-69
|
|
|
|
|
|
70+
|
|
|
|
|
|
Mammography as part of the population screening programme
|
|
|
|
|
|
|
|
|
20-29
|
|
|
|
Managed by RGC and VHR screening programme
|
|
|
30-39
|
|
|
|
|
|
40-49
|
|
|
|
|
|
50-59
|
|
|
|
|
|
60-69
|
|
|
|
|
|
70+
|
|
|
|
|
|
5. For people referred into your family history service, does your unit have any additional inclusion criteria it uses to determine who can receive different types of support, in addition to the eligibility criteria outlined in NICE CG164 guidance, and if so, what are those criteria for:
Undertaking an initial family history risk assessment
|
NIL
|
Access to risk-reduction interventions, both chemoprevention and mastectomy
|
NIL
|
Access to enhanced surveillance screening
|
NIL
|